BiotechTube
SpyBiotech

SpyBiotech

Oxford, United Kingdom· Est.
spybiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $36.5M

Overview

SpyBiotech is a private, clinical-stage biotech pioneering a versatile vaccine platform technology centered on the SpyTag/SpyCatcher protein ligation system. This 'plug-and-play' approach allows for the efficient and irreversible conjugation of target antigens to various delivery platforms, aiming to generate stronger and more targeted immune responses. The company's lead program is a Phase I cytomegalovirus (CMV) vaccine candidate, with a broader pipeline exploring applications in viral, bacterial, and parasitic diseases, as well as oncology. SpyBiotech's ambition is to address major unmet medical needs by accelerating and simplifying vaccine development.

Infectious DiseasesOncologyChronic Diseases

Technology Platform

Proprietary SpyTag/SpyCatcher protein 'superglue' system enabling rapid, precise, and irreversible covalent conjugation of antigens to various delivery platforms (Virus-Like Particles, viral vectors) for vaccine development.

Funding History

2
Total raised:$36.5M
Series A$32.5M
Seed$4M

Opportunities

The lead CMV vaccine targets a major unmet need with blockbuster potential, supported by high priority from regulatory bodies.
The versatile 'plug-and-play' platform technology offers significant partnership potential across infectious diseases, oncology, and pandemic preparedness, enabling faster and more efficient vaccine development.

Risk Factors

The company faces high clinical risk, as failure of its lead Phase I CMV candidate would significantly devalue its platform.
As a pre-revenue private company, it is dependent on successful fundraising in a competitive capital environment, and its novel technology must still prove itself against established and emerging vaccine platforms.

Competitive Landscape

SpyBiotech competes in the novel vaccine platform space against established technologies (mRNA, adenovirus vectors, traditional VLPs) and other emerging protein engineering approaches. Its differentiation lies in the precision and irreversibility of its SpyTag/SpyCatcher conjugation, but it must demonstrate clinical superiority or significant practical advantages in speed and versatility to capture market and partnership interest.

More companies in United Kingdom →